Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. [clinicaltrials:NCT01091532]A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. [clinicaltrials:NCT01415102]A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels [clinicaltrials:NCT02010944]
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT02318342 [clinicaltrials_resource:276b82cb195e6cb0d2b6756ac316a553]eligibility for clinicaltrials:NCT01684215 [clinicaltrials_resource:442329be12ac0c1354181ff4d97eb5e9]eligibility for clinicaltrials:NCT01933477 [clinicaltrials_resource:5ecf8366722c1001abf4277d8bc9f211]eligibility for clinicaltrials:NCT01430585 [clinicaltrials_resource:7a7b704ef3c99d97bce0f75f2648e79b]eligibility for clinicaltrials:NCT00473746 [clinicaltrials_resource:ca42b01b79c70077d7058b7ba1414078]eligibility for clinicaltrials:NCT01938573 [clinicaltrials_resource:ffbfbf9c49408323ef25b665988d80f8]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT02318342 [clinicaltrials_resource:276b82cb195e6cb0d2b6756ac316a553]eligibility for clinicaltrials:NCT01684215 [clinicaltrials_resource:442329be12ac0c1354181ff4d97eb5e9]eligibility for clinicaltrials:NCT01933477 [clinicaltrials_resource:5ecf8366722c1001abf4277d8bc9f211]eligibility for clinicaltrials:NCT01430585 [clinicaltrials_resource:7a7b704ef3c99d97bce0f75f2648e79b]eligibility for clinicaltrials:NCT00473746 [clinicaltrials_resource:ca42b01b79c70077d7058b7ba1414078]eligibility for clinicaltrials:NCT01938573 [clinicaltrials_resource:ffbfbf9c49408323ef25b665988d80f8]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites [clinicaltrials:NCT00000111]AIT-082 Phase 1B Study [clinicaltrials:NCT00000180]Cocaine in Parotid Saliva, Blood and Urine - 4 [clinicaltrials:NCT00000190]Piracetam for Treatment of Cocaine Addiction - 3 [clinicaltrials:NCT00000198]Piracetam for Treatment of Cocaine Addiction, Phase II - 4 [clinicaltrials:NCT00000199]Buprenorphine Dose Alteration Study - 1 [clinicaltrials:NCT00000219]Gradual Vs. Rapid Buprenorphine Detoxification - 2 [clinicaltrials:NCT00000220]Alternate-Day Buprenorphine Administration. Phase I - 3 [clinicaltrials:NCT00000221]Alternate-Day Buprenorphine Administration. Phase II - 4 [clinicaltrials:NCT00000222]Alternate-Day Buprenorphine. Phase V - 6 [clinicaltrials:NCT00000224]Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 [clinicaltrials:NCT00000276]Glutaminergic Agents for Cocaine Abuse - 5 [clinicaltrials:NCT00000280]Effects of Phenytoin on Cocaine Use in Humans - 2 [clinicaltrials:NCT00000285]Stress Hormones and Human Cocaine Use - 7 [clinicaltrials:NCT00000290]Acute Withdrawal From Smoked Cocaine - 9 [clinicaltrials:NCT00000292]Amphetamine Cocaine Interaction Study - 2 [clinicaltrials:NCT00000305]Alterations in Serotonergic Functions in Cocaine Addicts - 1 [clinicaltrials:NCT00000312]Predictive Values of Serotonergic Alterations for Outcome - 2 [clinicaltrials:NCT00000313]Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1 [clinicaltrials:NCT00000315]Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2 [clinicaltrials:NCT00000316]Therapeutic Potential of Kappa-Opioids Against Cocaine - 1 [clinicaltrials:NCT00000323]Psychostimulant Abuse - Novel Treatment Approaches - 1 [clinicaltrials:NCT00000325]Infusion Laboratory: Protocol 1 - Selegeline - 2 [clinicaltrials:NCT00000337]Infusion Laboratory: Protocol 2 (Lisuride) - 3 [clinicaltrials:NCT00000338]Infusion Laboratory: Protocol 3 (Risperidone) - 4 [clinicaltrials:NCT00000339]Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10 [clinicaltrials:NCT00000345]Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13 [clinicaltrials:NCT00000348]Infusion Laboratory: Protocol 5 (Flupenthixol) - 14 [clinicaltrials:NCT00000349]Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 [clinicaltrials:NCT00000350]Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3 [clinicaltrials:NCT00000354]Effects of Buprenorphine and Naloxone in Opiate Addicts - 4 [clinicaltrials:NCT00000355]Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7 [clinicaltrials:NCT00000358]A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients. [clinicaltrials:NCT00000391]A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS). [clinicaltrials:NCT00000393]clinicaltrials:NCT00000431A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine [clinicaltrials:NCT00000628]The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients. [clinicaltrials:NCT00000629]Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn) [clinicaltrials:NCT00000630]A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn) [clinicaltrials:NCT00000631]A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59 [clinicaltrials:NCT00000632]
phase [clinicaltrials_vocabulary:phase]
Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]
Bio2RDF identifier
ee4650e51426c7487977eeea8e7e6850
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850
identifier
clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850
title
Phase 1
@en
type
label
Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]
@en